Outcome of Pomalidomide Therapy in Relapsed /Refractory Myeloma: A Uk Multi-Centre Experience
Nicola Maciocia(University College London), Neil Rabin(University College London), Aviva Cerner(University College London Hospitals NHS Foundation Trust), Ali Rismani(Whittington Hospital), Edward Belsham(Portsmouth Hospitals NHS Trust), Simon Cheesman(Royal London Hospital), Matthew Streetly(King's College - North Carolina), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Hanna Renshaw(University College London Hospitals NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Shirley D’Sa(University College Hospital), Stephen Schey(University College Hospital), Faye Sharpley(Oxford University Hospitals NHS Trust)
Cited by 3
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315
Guidelines for the diagnosis and management of multiple myeloma 2011
|British Journal of Haematology|2011|305